ACUSON CORP
SC 14D9, EX-99.(A)(1), 2000-10-05
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: ACUSON CORP, SC 14D9, 2000-10-05
Next: COMPUTRAC INC, 4, 2000-10-05



<PAGE>

                                                                   EXHIBIT a(1)

                 LETTER TO STOCKHOLDERS DATED OCTOBER 5, 2000

                               [LOGO OF ACUSON]

Acuson Corporation
1220 Charleston Road
Mountain View, California 94043

October 5, 2000

Dear Stockholder:

  I am pleased to inform you that Acuson Corporation has entered into a merger
agreement with Siemens Corporation, pursuant to which a wholly-owned
subsidiary of Siemens has commenced a tender offer to purchase all of the
outstanding shares of Acuson's common stock for $23.00 per share in cash. The
tender offer is conditioned upon, among other things, at least a specified
minimum number of Acuson's shares outstanding being tendered and not withdrawn
and the receipt of required regulatory approvals. If completed, the tender
offer will be followed by a merger in which each share of Acuson common stock
not purchased in the tender offer will be converted into the right to receive
$23.00 per share in cash.

  Your Board of Directors has determined that the terms of the Siemens offer
and the merger are fair to and in the best interests of Acuson's stockholders,
and recommends that Acuson's stockholders accept the Siemens offer, tender
their shares of Acuson common stock pursuant to the offer and, if required
under the Delaware General Corporation Law or Acuson's Certificate of
Incorporation or Bylaws, vote to adopt the Merger Agreement.

  In arriving at its recommendation, the Board of Directors considered a
number of factors, as described in the attached Schedule 14D-9. Included as an
annex to the attached Schedule 14D-9 is the written opinion dated September
26, 2000 of Acuson's financial advisor, UBS Warburg LLC, to the effect that,
as of such date and based on and subject to the matters stated in such
opinion, the $23.00 per share cash consideration to be received in the tender
offer and the merger by the holders of Acuson common stock was fair, from a
financial point of view, to such holders (other than Siemens and its
affiliates). You should read the opinion carefully and in its entirety for a
description of the assumptions made, procedures followed, matters considered
and limitations on the review undertaken by UBS Warburg LLC in rendering its
opinion.

  Enclosed are Siemens' Offer to Purchase, dated October 5, 2000 and Letter of
Transmittal and related documents. These documents set forth the terms and
conditions of the tender offer. The Schedule 14D-9 describes in more detail
the reasons for your Board's conclusions and contains other information
relating to the tender offer. We urge you to consider this information
carefully.
                                          /s/ Samuel H. Maslak
                                          Samuel H. Maslak
                                          Chairman of the Board and
                                          Chief Executive Officer


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission